BMC Ophthalmology

Table 2 BCVA at different time points of three groups

From: A pilot study of viscoelastic agent to prevent recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy

	Baseline BCVA (logMAR)	BCVA at 1wk (logMAR)	BCVA at 6 months (logMAR)
VA group	1.37 ± 0.52	0.73 ± 0.39^a	0.46 ± 0.37^a
TA group	1.38 ± 0.46	0.74 ± 0.37^a	0.71 ± 0.56^a
BSS group	1.31 ± 0.49	0.83 ± 0.52^a	0.58 ± 0.39^a

^a compared with baseline, P < 0.05

Back to article page

ISSN: 1471-2415

Contact us

General enquiries: journalsubmissions@springernature.com